Ultrasound neural maps identify pathology-defined prostate cancer tissue
Source check: Source checked. Not independent scientific confirmation.
Finding: A three-dimensional CNN and multilayer perceptron combined quantitative ultrasound features to map clinically significant prostate cancer. Development involved 250 patients, followed by 77 later-enrolled patients; reported voxel-level AUC was 0.884 in that later group. Pathology registration and a surgical-enriched cohort limit interpretation. This does not establish patient-level diagnostic accuracy, biopsy benefit or equivalence to MRI-guided care.
Technology: Three-dimensional convolutional neural network; multilayer perceptron
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Three CNN feature branches learn ultrasound patterns and an MLP combines them into voxel-level cancer probability maps.
- Test and result
- Patient-partitioned development and temporally separate same-centre testing, using reconstructed prostatectomy pathology or negative MRI/biopsy references.
- Limitation / still unknown
- Lesion/patient-level clinical performance and treatment benefit remain unestablished; entire-dataset feature standardization and registration uncertainty limit a strictly untouched-test interpretation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13212788/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant model Methods, Results and limitations; exact primary identity and current primary PubMed correction/retraction relationships checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.